author-photo

Rachel Courtney

Pfizer

23

Papers

1223

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

2015 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (87)
A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (55)
587 Phase 1 Dose-escalation Study of PF-04449913, an Oral Hedgehog Inhibitor in Patients with Select Solid Tumors

2012 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 906: Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

2012 Blood
Show All
- Source
- Cite
- Save
Citations (239)
Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.

2011 Ophthalmology
Show All
- Source
- Cite
- Save
Citations (19)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

2011 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (212)
Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies

2011 Blood
Show All
- Source
- Cite
- Save
Citations (45)
Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (26)
Dose-Escalating, Double-Masked, Vehicle-Controlled Trial of the IOP-Reducing Effect of the EP2 Agonist PF-04217329

2010 Investigative Ophthalmology & Visual Science
Show All
- Source
- Cite
- Save
Citations (2)